MedTrace Logo

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

NCT05054348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-06-04

No results posted yet for this study

Summary

The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

IO-108

IO-108 given as monotherapy

BIOLOGICAL

IO-108 + pembrolizumab combination therapy

IO-108 and fixed dose pembrolizumab combination therapy

BIOLOGICAL

IO-108 + cemiplimab combination therapy

IO-108 and fixed dose cemiplimab combination therapy

Sponsors & Collaborators

Principal Investigators

  • Wen Hong Lin, MD · Immune-Onc Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2024-04-29
Completion
2024-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054348 on ClinicalTrials.gov